Abstract 147P
Background
In 2017, the 8th edition of the Union for International Cancer Control TNM classification (TNM8) was published and clinical staging system was newly defined. Recently, this clinical staging reportedly predicted the prognosis in patients with gastric cancer (GC). Different from common GC, the diagnosis and the treatment of adenocarcinoma of the esophagogastric junction (AEG) have been controversial. Moreover, its incidence also has increased in Japan. The purpose of this study was to clarify whether the prognosis of patients with Siewert type II/III tumors was appropriately stratified by the clinical staging system.
Methods
Patients who were diagnosed with AEG type II/III and received gastrectomy or esophagectomy between 1986 and 2014 at Kanagawa Cancer Center were included in this study. Patients received neoadjuvant chemotherapy were excluded.
Results
A total of 196 patients were examined, 123 (63%) patients had type II tumor and 73 (37%) had type III. 41 patients were classified to clinical stage I, 40 were to stage II, 104 were to stage III, and 11 were to stage IV, respectively. The median follow-up period of the survivors was 58.3 months. The 5-year overall survival rate was 48.8 % in whole cohort and were 82.5% in stage I, 70.0% in stage II, 31.7% in stage III, and 9.1% in stage IV. The hazard ratio to stage I was 1.93 in stage II, 5.68 in stage III, and 11.8 in stage IV, which increased in a stepwise manner with the stage.
Conclusions
The clinical staging system of TNM8 could appropriately stratify the prognosis of the patients with Siewert type II/III tumors.
Clinical trial identification
This study was approved by the institutional review board of Kanagawa Cancer Center. (Epidemiological Study-23).
Editorial acknowledgement
Legal entity responsible for the study
Kanagawa Cancer Center.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
133P - Which patient subgroup needs more attention in early treatment failure? A matched cohort study of treatment failure patterns in locally advanced gastric cancer
Presenter: Dong Wu
Session: e-Poster Display Session
134P - Effect of preoperative tumour under-staging on the long-term survival of patients undergoing radical gastrectomy for gastric cancer
Presenter: Mi Lin
Session: e-Poster Display Session
135P - Significance of lymphatic invasion in the indication for additional gastrectomy after endoscopic treatment
Presenter: Hirohito Fujikawa
Session: e-Poster Display Session
136P - Modified ypTNM staging classification for gastric cancer after neoadjuvant therapy: A multi-institutional study
Presenter: Wen-Wu Qiu
Session: e-Poster Display Session
137P - Clinical utility of circulating tumour DNA (ctDNA) in resectable gastric cancer (GC)
Presenter: Mikhail Fedyanin
Session: e-Poster Display Session
138P - Prognostic importance of dynamic changes in systemic inflammatory markers for patients with gastric cancer
Presenter: Ying-Qi Huang
Session: e-Poster Display Session
139P - An intraoperative model for predicting survival and deciding therapeutic schedules: A comprehensive analysis of peritoneal metastasis in patients with advanced gastric cancer
Presenter: Zhi-Yu Liu
Session: e-Poster Display Session
140P - Preoperative and postoperative C-reactive protein levels predict recurrence and chemotherapy benefit in gastric cancer
Presenter: Li-Li Shen
Session: e-Poster Display Session
141P - Low expression of CDK5RAP3 and UFM1 indicates poor prognosis in patients with gastric cancer
Presenter: Ning-Zi Lian
Session: e-Poster Display Session
142P - Prognostic analysis of patients with intra-abdominal infectious complications after laparoscopy and open radical gastrectomy for gastric cancer: A propensity score-matching analysis
Presenter: Si-Jin Que
Session: e-Poster Display Session